Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | SPR | P35270 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26509089 | 0.94 | MEN1 (0.46) | ACACBENPP2ATXN2MEN1KMT2A | |
| SCHEMBL26099471 | 0.91 | MEN1 (0.52) | MEN1KMT2ACRBNDDB1 | |
| SCHEMBL31586864 | 0.88 | ACACB (0.47) | ACACBENPP2ATXN2SCD5CRBN | |
| SCHEMBL31161582 | 0.87 | CRBN (0.37) | ACACBMEN1KMT2ACRBNDDB1 | |
| SCHEMBL31161337 | 0.85 | CRBN (0.37) | ACACBENPP2ATXN2MEN1KMT2A | |
| SCHEMBL23121362 | 0.85 | KMT2A (0.44) | MEN1KMT2ACRBNDDB1 | |
| SCHEMBL30874160 | 0.85 | ACACB (0.47) | ACACBENPP2ATXN2SCD5CRBN | |
| SCHEMBL27123605 | 0.85 | SOS1 (0.43) | ACACBMEN1KMT2ACRBNDDB1 | |
| SCHEMBL30874149 | 0.84 | ACACB (0.45) | ACACBMEN1KMT2ACRBNDDB1 | |
| SCHEMBL26100969 | 0.84 | MEN1 (0.43) | ENPP2MEN1KMT2ACRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | ACACB 2103/4885ENPP2 822/4885ATXN2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.